Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
2.845
-0.140 (-4.69%)
At close: Apr 28, 2026, 4:00 PM EDT
2.850
+0.005 (0.18%)
After-hours: Apr 28, 2026, 7:46 PM EDT
Processa Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 6.18 | 4.78 | 5.66 | 8.76 | 4.69 | |
| Research & Development | 7.81 | 7.27 | 5.8 | 11.49 | 6.88 | |
| Operating Expenses | 13.99 | 12.05 | 11.46 | 20.26 | 11.57 | |
| Operating Income | -13.99 | -12.05 | -11.46 | -20.26 | -11.57 | |
| Interest & Investment Income | 0.11 | 0.2 | 0.34 | 0.1 | 0.01 | |
| Other Non Operating Income (Expenses) | 0.32 | - | - | - | - | |
| EBT Excluding Unusual Items | -13.56 | -11.85 | -11.12 | -20.16 | -11.56 | |
| Asset Writedown | - | - | - | -7.27 | - | |
| Other Unusual Items | - | - | - | - | 0.16 | |
| Pretax Income | -13.56 | -11.85 | -11.12 | -27.42 | -11.96 | |
| Income Tax Expense | - | - | - | - | -0.53 | |
| Net Income | -13.56 | -11.85 | -11.12 | -27.42 | -11.43 | |
| Net Income to Common | -13.56 | -11.85 | -11.12 | -27.42 | -11.43 | |
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | |
| Shares Change (YoY) | 969.33% | 133.38% | 62.83% | 5.16% | 104.27% | |
| EPS (Basic) | -10.36 | -96.78 | -211.99 | -851.18 | -372.97 | |
| EPS (Diluted) | -10.36 | -96.78 | -211.99 | -851.18 | -372.97 | |
| Free Cash Flow | -11.39 | -11.25 | -8.07 | -9.61 | -8.72 | |
| Free Cash Flow Per Share | -8.70 | -91.87 | -153.75 | -298.12 | -284.52 | |
| EBITDA | -13.99 | -12.05 | -11.46 | -19.47 | -10.78 | |
| D&A For EBITDA | 0 | 0 | 0 | 0.79 | 0.79 | |
| EBIT | -13.99 | -12.05 | -11.46 | -20.26 | -11.57 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.